1. Home
  2. Research and Funding
  3. Current Funding Opportunities
  4. Therapeutic Targeting Of The Human Islet Environment (UC4)

Therapeutic Targeting Of The Human Islet Environment (UC4)

This Funding Opportunity Announcement (FOA) solicits applications for projects to develop strategies to target the human pancreatic environment in-vivo to deliver cell-based therapeutics, regulatory molecules or gene constructs that can protect or replenish the functional beta cell mass, or to develop synthetic sentinel biomarkers to safely monitor beta cell stress or disease initiation prior to the appearance of autoantibodies in individuals at risk of developing Type 1 Diabetes (T1D). Successful applicants will join the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase functional human beta cell mass in vivo through the controlled manipulation of beta cell replication, islet cell plasticity, or the reprogramming of pancreatic non-beta cells into beta-like cells. CTAR is part of the Human Islet Research Network (HIRN).

Funding Opportunity Details


Olivier Blondel, Ph.D.

Key Dates


February 22, 2017

March 22, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.